May 28, 2014
Synageva BioPharma Corp.
("Synageva") (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that
Sanj K. Patel
, President and Chief Executive Officer of Synageva will present at the Jefferies Global Healthcare Conference in
New York City
Thursday, June 5, 2014
9:00 a.m. EDT
, and at the Goldman Sachs Global Healthcare Conference in
Rancho Palos Verdes, CA
Wednesday, June 11, 2014
9:20 a.m. PDT
. The presentations will be webcast live and may be accessed from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at
Synageva routinely posts information that may be important to investors in the "Investor Relations" section of the company's website at
. Synageva encourages investors and potential investors to consult this website regularly for important information about the company.
Further information regarding Synageva BioPharma Corp. is available at
This news release contains "forward-looking statements". Such statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "intend," "believe," "may," "will," "estimate," "forecast," "project," or words of similar meaning. These forward-looking statements address, among other matters, our plans to develop our product candidates and pipeline programs, and their potential to address unmet medical need and impact disease course. Many factors may cause actual results to differ materially from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties some of which are known, including, unanticipated costs or delays in our research and development programs, risk of delays in completing our clinical trials, risk that the outcomes of our preclinical or clinical trials may not support registration or further development of our product candidates due to safety, efficacy or other reasons, the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory authorities, and the risks identified under the heading "Risk Factors" in Synageva's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on
May 1, 2014
and other filings Synageva periodically makes with the SEC, and others of which are not known. Preclinical and clinical trial data are subject to differing interpretations, and regulatory agencies, as well as medical and scientific experts, may not share Synageva's views regarding this data or its implications. Synageva may encounter problems or delays in preclinical and clinical development and the regulatory process. No forward-looking statement is a guarantee of future results or events, and investors should avoid placing undue reliance on such statements. Synageva undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
"Dedicated to Rare Diseases®" is a registered trademark of Synageva. "Synageva BioPharma™" is a trademark of Synageva BioPharma Corp.